Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P36405
UPID:
ARL3_HUMAN
Alternative names:
-
Alternative UPACC:
P36405; B2R6C7; Q53X83; Q5JSM2
Background:
ADP-ribosylation factor-like protein 3 plays a pivotal role in cellular processes such as cytokinesis and cilia signaling. It operates by cycling between inactive GDP-bound and active GTP-bound forms, a process regulated by guanine nucleotide exchange factors and GTPase-activating proteins. This protein is essential for targeting specific proteins to the cilium, including myristoylated NPHP3 and prenylated INPP5E, facilitating crucial cellular signaling pathways.
Therapeutic significance:
Given its involvement in Joubert syndrome 35 and Retinitis pigmentosa 83, understanding the role of ADP-ribosylation factor-like protein 3 could open doors to potential therapeutic strategies. Its critical function in cilia signaling and protein targeting to the cilium highlights its potential as a target for therapeutic intervention in these diseases.